DOCSLIB.ORG

Down Syndrome Acute Lymphoblastic Leukemia, a Highly Heterogeneous

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

Hertzberg, L; Vendramini, E; Ganmore, I; Cazzaniga, G; Schmitz, M; Chalker, J; Shiloh, R; Iacobucci, I; Shochat, C; Zeligson, S; Cario, G; Stanulla, M; Strehl, S; Russell, L J; Harrison, C J; Bornhauser, B; Yoda, A; Rechavi, G; Bercovich, D; Borkhardt, A; Kempski, H; te Kronnie, G; Bourquin, J P; Domany, E; Izraeli, S (2010). Down syndrome acute lymphoblastic leukemia, a highly heterogeneous disease in which aberrant expression of CRLF2 is associated with mutated JAK2: a report from the International BFM Study Group. Blood, 115(5):1006-1017. University of Zurich Postprint available at: Zurich Open Repository and Archive http://www.zora.uzh.ch Posted at the Zurich Open Repository and Archive, University of Zurich. http://www.zora.uzh.ch Winterthurerstr. 190 Originally published at: CH-8057 Zurich Blood 2010, 115(5):1006-1017. http://www.zora.uzh.ch Year: 2010 Down syndrome acute lymphoblastic leukemia, a highly heterogeneous disease in which aberrant expression of CRLF2 is associated with mutated JAK2: a report from the International BFM Study Group Hertzberg, L; Vendramini, E; Ganmore, I; Cazzaniga, G; Schmitz, M; Chalker, J; Shiloh, R; Iacobucci, I; Shochat, C; Zeligson, S; Cario, G; Stanulla, M; Strehl, S; Russell, L J; Harrison, C J; Bornhauser, B; Yoda, A; Rechavi, G; Bercovich, D; Borkhardt, A; Kempski, H; te Kronnie, G; Bourquin, J P; Domany, E; Izraeli, S Hertzberg, L; Vendramini, E; Ganmore, I; Cazzaniga, G; Schmitz, M; Chalker, J; Shiloh, R; Iacobucci, I; Shochat, C; Zeligson, S; Cario, G; Stanulla, M; Strehl, S; Russell, L J; Harrison, C J; Bornhauser, B; Yoda, A; Rechavi, G; Bercovich, D; Borkhardt, A; Kempski, H; te Kronnie, G; Bourquin, J P; Domany, E; Izraeli, S (2010). Down syndrome acute lymphoblastic leukemia, a highly heterogeneous disease in which aberrant expression of CRLF2 is associated with mutated JAK2: a report from the International BFM Study Group. Blood, 115(5):1006-1017. Postprint available at: http://www.zora.uzh.ch Posted at the Zurich Open Repository and Archive, University of Zurich. http://www.zora.uzh.ch Originally published at: Blood 2010, 115(5):1006-1017. Down syndrome acute lymphoblastic leukemia, a highly heterogeneous disease in which aberrant expression of CRLF2 is associated with mutated JAK2: a report from the International BFM Study Group Abstract We report gene expression and other analyses to elucidate the molecular characteristics of acute lymphoblastic leukemia (ALL) in children with Down syndrome (DS). We find that by gene expression DS-ALL is a highly heterogeneous disease not definable as a unique entity. Nevertheless, 62% (33/53) of the DS-ALL samples analyzed were characterized by high expression of the type I cytokine receptor CRLF2 caused by either immunoglobulin heavy locus (IgH@) translocations or by interstitial deletions creating chimeric transcripts P2RY8-CRLF2. In 3 of these 33 patients, a novel activating somatic mutation, F232C in CRLF2, was identified. Consistent with our previous research, mutations in R683 of JAK2 were identified in 10 specimens (19% of the patients) and, interestingly, all 10 had high CRLF2 expression. Cytokine receptor-like factor 2 (CRLF2) and mutated Janus kinase 2 (Jak2) cooperated in conferring cytokine-independent growth to BaF3 pro-B cells. Intriguingly, the gene expression signature of DS-ALL is enriched with DNA damage and BCL6 responsive genes, suggesting the possibility of B-cell lymphocytic genomic instability. Thus, DS confers increased risk for genetically highly diverse ALLs with frequent overexpression of CRLF2, associated with activating mutations in the receptor itself or in JAK2. Our data also suggest that the majority of DS children with ALL may benefit from therapy blocking the CRLF2/JAK2 pathways. LYMPHOID NEOPLASIA Down syndrome acute lymphoblastic leukemia, a highly heterogeneous disease in which aberrant expression of CRLF2 is associated with mutated JAK2: a report from the International BFM Study Group *Libi Hertzberg,1-3 *Elena Vendramini,4 *Ithamar Ganmore,1,2 Gianni Cazzaniga,5 Maike Schmitz,6 Jane Chalker,7 Ruth Shiloh,1 Ilaria Iacobucci,8 Chen Shochat,1,2,9 Sharon Zeligson,1 Gunnar Cario,10 Martin Stanulla,10 Sabine Strehl,11 Lisa J. Russell,12 Christine J. Harrison,12 Beat Bornhauser,6 Akinori Yoda,13 Gideon Rechavi,1,2 Dani Bercovich,9 Arndt Borkhardt,14 Helena Kempski,7 †Geertruy te Kronnie,4 †Jean-Pierre Bourquin,6 †Eytan Domany,3 and †Shai Izraeli1,2 1Pediatric Hemato-Oncology and the Cancer Research Center, Sheba Medical Center, Tel Hashomer, Ramat-Gan, Israel; 2Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; 3Department of Physics of Complex Systems, Weizmann Institute of Science, Rehovot, Israel; 4Hemato-Oncology Laboratory, Department of Pediatrics, University of Padova, Padova, Italy; 5Centro Ricerca Tettamanti, Clinica Paediatrica Universita` di Milano-Bicocca, Ospedale San Gerardo, Monza, Italy; 6Department of Pediatric Oncology, University Children’s Hospital, University of Zurich, Zurich, Switzerland; 7Paediatric Malignancy Cytogenetics Unit, Camelia Botnar Laboratories, Great Ormond Street Hospital & Institute of Child Health, London, United Kingdom; 8Department of Hematology/Oncology L. and A. Sera`gnoli, University of Bologna, Bologna, Italy; 9Human Molecular Genetics and Pharmacogenetics Laboratory, Migal–Galilee Biotechnology Center, Kiryat Shmona, and Tel-Hai Academic College, Tel Hai, Israel; 10Department of Pediatrics, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany; 11Children’s Cancer Research Institute, St Anna Kinderkrebsforschung, Vienna, Austria; 12Leukaemia Research Cytogenetics Group, Northern Institute for Cancer Research, Newcastle University, Newcastle, United Kingdom; 13Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; and 14Clinic of Pediatric Oncology, Hematology, and Clinical Immunology, Children’s University Hospital, Heinrich Heine University, Du¨sseldorf, Germany We report gene expression and other analy- chimeric transcripts P2RY8-CRLF2.In3of enriched with DNA damage and BCL6 re- ses to elucidate the molecular characteris- these 33 patients, a novel activating somatic sponsive genes, suggesting the possibility tics of acute lymphoblastic leukemia (ALL) mutation, F232C in CRLF2, was identified. of B-cell lymphocytic genomic instability. in children with Down syndrome (DS). We Consistent with our previous research, mu- Thus, DS confers increased risk for geneti- find that by gene expression DS-ALL is a tations in R683 of JAK2 were identified in cally highly diverse ALLs with frequent over- highly heterogeneous disease not definable 10 specimens (19% of the patients) and, expression of CRLF2, associated with acti- as a unique entity. Nevertheless, 62% (33/53) interestingly, all 10 had high CRLF2 expres- vating mutations in the receptor itself or in of the DS-ALL samples analyzed were char- sion. Cytokine receptor-like factor 2 (CRLF2) JAK2. Our data also suggest that the major- acterized by high expression of the type I and mutated Janus kinase 2 (Jak2) cooper- ity of DS children with ALL may benefit from cytokine receptor CRLF2 caused by either ated in conferring cytokine-independent therapy blocking the CRLF2/JAK2 path- immunoglobulin heavy locus (IgH@) translo- growth to BaF3 pro-B cells. Intriguingly, the ways. (Blood. 2010;115:1006-1017) cations or by interstitial deletions creating gene expression signature of DS-ALL is Introduction Children with Down syndrome (DS) have a higher rate of acute To characterize additional molecular abnormalities in DS-ALL, lymphoblastic leukemia (DS-ALL). DS-ALLs are mostly of B-cell we performed genomic analysis of a large group of DS-ALLs. This precursor (BCP) origin and similar in the age of diagnosis and analysis reveals, next to a striking heterogeneity of these leuke- immunophenotype to high hyperdiploid (HD) or TEL-AML1 ALLs,1 mias, an aberrant expression of the cytokine receptor CRLF2 in the 2 most common genetic subtypes of childhood ALL. Given that 62% of the patients, associated with somatic activating mutations these cytogenetic abnormalities are less frequent in DS-ALL,2 the in JAK2 or in the receptor itself. existence of unique collaborating somatic genetic events in DS- ALL, similar to the GATA1 mutation in DS-acute megakaryoblastic leukemia,3 has been postulated. Methods We and others reported the presence of somatic activating mutations in JAK2 in approximately 20% of DS-ALLs.4-6 Similar mutations are Patient samples present in approximately 10% of high-risk ALLs in non-DS children, RNA and DNA were derived from diagnostic bone marrow samples of 7 corresponding to approximately 3% of unselected childhood ALLs. We children with DS and BCP-ALL enrolled on treatment protocols with an hypothesized that the mutated Janus kinase 2 (JAK2) may cooperate informed consent and approval of the ethics committees of all participating with a type I cytokine receptor that is aberrantly expressed in DS-ALL.4 institutions in accordance with the Declaration of Helsinki. Samples were Submitted August 5, 2009; accepted November 1, 2009. Prepublished online The online version of this article contains a data supplement. as Blood First Edition paper, November 24, 2009; DOI 10.1182/blood-2009-08- The publication costs of this article were defrayed in part by page charge 235408. payment. Therefore, and solely to indicate this fact, this article is hereby *L.H., E.V., and I.G. are co–first authors. marked ‘‘advertisement’’ in accordance with 18 USC section 1734. †G.t.K., J.-P.B., E.D., and S.I. are co–senior authors. © 2010 by The American Society of Hematology 1006 BLOOD, 4 FEBRUARY 2010 ⅐ VOLUME 115, NUMBER 5 BLOOD, 4 FEBRUARY 2010 ⅐ VOLUME 115, NUMBER 5 GENOMIC ANALYSIS OF DS-ALL 1007 Table 1. Description of the gene expression datasets analyzed No. samples Dataset symbol Total DS-ALL HD TEL-AML1 Other Platform AIEOP* 97 25 26 29 4 E2A-PBX1, 6 MLL, 7 BCR-ABL Affymetrix HG-U133 Plus 2.0 ICH 15 6 5 4 Affymetrix HG-U133 Plus 2.0 BFM8* ϩ St Jude10† 36 7 12 17 Affymetrix HG-U133A IL† 27 11 10 6 Affymetrix Exon 1.0 ST AIEOP indicates Associazione Italiana Ematologia Oncologia Pediatrica; ICH, Institute Child Health; BFM, Berlin-Frankfurt-Munster; and IL, Israel.
Recommended publications
  • Molecular Profile of Tumor-Specific CD8+ T Cell Hypofunction in a Transplantable Murine Cancer Model

    Molecular Profile of Tumor-Specific CD8+ T Cell Hypofunction in a Transplantable Murine Cancer Model

    Downloaded from http://www.jimmunol.org/ by guest on September 25, 2021 T + is online at: average * The Journal of Immunology , 34 of which you can access for free at: 2016; 197:1477-1488; Prepublished online 1 July from submission to initial decision 4 weeks from acceptance to publication 2016; doi: 10.4049/jimmunol.1600589 http://www.jimmunol.org/content/197/4/1477 Molecular Profile of Tumor-Specific CD8 Cell Hypofunction in a Transplantable Murine Cancer Model Katherine A. Waugh, Sonia M. Leach, Brandon L. Moore, Tullia C. Bruno, Jonathan D. Buhrman and Jill E. Slansky J Immunol cites 95 articles Submit online. Every submission reviewed by practicing scientists ? is published twice each month by Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts http://jimmunol.org/subscription Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html http://www.jimmunol.org/content/suppl/2016/07/01/jimmunol.160058 9.DCSupplemental This article http://www.jimmunol.org/content/197/4/1477.full#ref-list-1 Information about subscribing to The JI No Triage! Fast Publication! Rapid Reviews! 30 days* Why • • • Material References Permissions Email Alerts Subscription Supplementary The Journal of Immunology The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2016 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. This information is current as of September 25, 2021. The Journal of Immunology Molecular Profile of Tumor-Specific CD8+ T Cell Hypofunction in a Transplantable Murine Cancer Model Katherine A.
  • Cytokine Nomenclature

    Cytokine Nomenclature

    RayBiotech, Inc. The protein array pioneer company Cytokine Nomenclature Cytokine Name Official Full Name Genbank Related Names Symbol 4-1BB TNFRSF Tumor necrosis factor NP_001552 CD137, ILA, 4-1BB ligand receptor 9 receptor superfamily .2. member 9 6Ckine CCL21 6-Cysteine Chemokine NM_002989 Small-inducible cytokine A21, Beta chemokine exodus-2, Secondary lymphoid-tissue chemokine, SLC, SCYA21 ACE ACE Angiotensin-converting NP_000780 CD143, DCP, DCP1 enzyme .1. NP_690043 .1. ACE-2 ACE2 Angiotensin-converting NP_068576 ACE-related carboxypeptidase, enzyme 2 .1 Angiotensin-converting enzyme homolog ACTH ACTH Adrenocorticotropic NP_000930 POMC, Pro-opiomelanocortin, hormone .1. Corticotropin-lipotropin, NPP, NP_001030 Melanotropin gamma, Gamma- 333.1 MSH, Potential peptide, Corticotropin, Melanotropin alpha, Alpha-MSH, Corticotropin-like intermediary peptide, CLIP, Lipotropin beta, Beta-LPH, Lipotropin gamma, Gamma-LPH, Melanotropin beta, Beta-MSH, Beta-endorphin, Met-enkephalin ACTHR ACTHR Adrenocorticotropic NP_000520 Melanocortin receptor 2, MC2-R hormone receptor .1 Activin A INHBA Activin A NM_002192 Activin beta-A chain, Erythroid differentiation protein, EDF, INHBA Activin B INHBB Activin B NM_002193 Inhibin beta B chain, Activin beta-B chain Activin C INHBC Activin C NM005538 Inhibin, beta C Activin RIA ACVR1 Activin receptor type-1 NM_001105 Activin receptor type I, ACTR-I, Serine/threonine-protein kinase receptor R1, SKR1, Activin receptor-like kinase 2, ALK-2, TGF-B superfamily receptor type I, TSR-I, ACVRLK2 Activin RIB ACVR1B
  • Targeting TSLP-Induced Tyrosine Kinase Signaling Pathways in CRLF2-Rearranged Ph-Like ALL Keith C.S

    Targeting TSLP-Induced Tyrosine Kinase Signaling Pathways in CRLF2-Rearranged Ph-Like ALL Keith C.S

    Published OnlineFirst August 14, 2020; DOI: 10.1158/1541-7786.MCR-19-1098 MOLECULAR CANCER RESEARCH | CANCER GENES AND NETWORKS Targeting TSLP-Induced Tyrosine Kinase Signaling Pathways in CRLF2-Rearranged Ph-like ALL Keith C.S. Sia1, Ling Zhong2, Chelsea Mayoh1, Murray D. Norris1,3, Michelle Haber1, Glenn M. Marshall1,4, Mark J. Raftery2, and Richard B. Lock1,3 ABSTRACT ◥ Philadelphia (Ph)-like acute lymphoblastic leukemia (ALL) is combination cytotoxicity assays using the tyrosine kinase inhi- characterized by aberrant activation of signaling pathways and bitors BMS-754807 and ponatinib that target IGF1R and FGFR1, high risk of relapse. Approximately 50% of Ph-like ALL cases respectively, revealed strong synergy against both cell line and overexpress cytokine receptor-like factor 2 (CRLF2) associated patient-derived xenograft (PDX) models of CRLF2r Ph-like ALL. with gene rearrangement. Activated by its ligand thymic stromal Further analyses also indicated off-target effects of ponatinib in lymphopoietin (TSLP), CRLF2 signaling is critical for the devel- the synergy, and novel association of the Ras-associated protein- opment, proliferation, and survival of normal lymphocytes. To 1 (Rap1) signaling pathway with TSLP signaling in CRLF2r Ph- examine activation of tyrosine kinases regulated by TSLP/CRLF2, like ALL. When tested in vivo, the BMS-754807/ponatinib com- phosphotyrosine (P-Tyr) profiling coupled with stable isotope bination exerted minimal efficacy against 2 Ph-like ALL PDXs, labeling of amino acids in cell culture (SILAC) was conducted associated with low achievable plasma drug concentrations. using two CRLF2-rearranged (CRLF2r) Ph-like ALL cell lines Although this study identified potential new targets in CRLF2r stimulated with TSLP.
  • Transcriptional Control of Tissue-Resident Memory T Cell Generation

    Transcriptional Control of Tissue-Resident Memory T Cell Generation

    Transcriptional control of tissue-resident memory T cell generation Filip Cvetkovski Submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy in the Graduate School of Arts and Sciences COLUMBIA UNIVERSITY 2019 © 2019 Filip Cvetkovski All rights reserved ABSTRACT Transcriptional control of tissue-resident memory T cell generation Filip Cvetkovski Tissue-resident memory T cells (TRM) are a non-circulating subset of memory that are maintained at sites of pathogen entry and mediate optimal protection against reinfection. Lung TRM can be generated in response to respiratory infection or vaccination, however, the molecular pathways involved in CD4+TRM establishment have not been defined. Here, we performed transcriptional profiling of influenza-specific lung CD4+TRM following influenza infection to identify pathways implicated in CD4+TRM generation and homeostasis. Lung CD4+TRM displayed a unique transcriptional profile distinct from spleen memory, including up-regulation of a gene network induced by the transcription factor IRF4, a known regulator of effector T cell differentiation. In addition, the gene expression profile of lung CD4+TRM was enriched in gene sets previously described in tissue-resident regulatory T cells. Up-regulation of immunomodulatory molecules such as CTLA-4, PD-1, and ICOS, suggested a potential regulatory role for CD4+TRM in tissues. Using loss-of-function genetic experiments in mice, we demonstrate that IRF4 is required for the generation of lung-localized pathogen-specific effector CD4+T cells during acute influenza infection. Influenza-specific IRF4−/− T cells failed to fully express CD44, and maintained high levels of CD62L compared to wild type, suggesting a defect in complete differentiation into lung-tropic effector T cells.
  • Dux4r, Znf384r and PAX5-P80R Mutated B-Cell Precursor Acute

    Dux4r, Znf384r and PAX5-P80R Mutated B-Cell Precursor Acute

    Acute Lymphoblastic Leukemia SUPPLEMENTARY APPENDIX DUX4r , ZNF384r and PAX5 -P80R mutated B-cell precursor acute lymphoblastic leukemia frequently undergo monocytic switch Michaela Novakova, 1,2,3* Marketa Zaliova, 1,2,3* Karel Fiser, 1,2* Barbora Vakrmanova, 1,2 Lucie Slamova, 1,2,3 Alena Musilova, 1,2 Monika Brüggemann, 4 Matthias Ritgen, 4 Eva Fronkova, 1,2,3 Tomas Kalina, 1,2,3 Jan Stary, 2,3 Lucie Winkowska, 1,2 Peter Svec, 5 Alexandra Kolenova, 5 Jan Stuchly, 1,2 Jan Zuna, 1,2,3 Jan Trka, 1,2,3 Ondrej Hrusak 1,2,3# and Ester Mejstrikova 1,2,3# 1CLIP - Childhood Leukemia Investigation Praguerague, Czech Republic; 2Department of Paediatric Hematology and Oncology, Second Faculty of Medicine, Charles University, Prague, Czech Republic; 3University Hospital Motol, Prague, Czech Republic; 4Department of In - ternal Medicine II, University Hospital Schleswig-Holstein, Kiel, Germany and 5Comenius University, National Institute of Children’s Dis - eases, Bratislava, Slovakia *MN, MZ and KF contributed equally as co-first authors. #OH and EM contributed equally as co-senior authors. ©2021 Ferrata Storti Foundation. This is an open-access paper. doi:10.3324/haematol. 2020.250423 Received: February 18, 2020. Accepted: June 25, 2020. Pre-published: July 9, 2020. Correspondence: ESTER MEJSTRIKOVA - [email protected] Table S1. S1a. List of antibodies used for diagnostic immunophenotyping. Antibody Fluorochrome Clone Catalogue number Manufacturer CD2 PE 39C1.5 A07744 Beckman Coulter CD3 FITC UCHT1 1F-202-T100 Exbio CD4 PE-Cy7
  • Practice Parameter for the Diagnosis and Management of Primary Immunodeficiency

    Practice Parameter for the Diagnosis and Management of Primary Immunodeficiency

    Practice parameter Practice parameter for the diagnosis and management of primary immunodeficiency Francisco A. Bonilla, MD, PhD, David A. Khan, MD, Zuhair K. Ballas, MD, Javier Chinen, MD, PhD, Michael M. Frank, MD, Joyce T. Hsu, MD, Michael Keller, MD, Lisa J. Kobrynski, MD, Hirsh D. Komarow, MD, Bruce Mazer, MD, Robert P. Nelson, Jr, MD, Jordan S. Orange, MD, PhD, John M. Routes, MD, William T. Shearer, MD, PhD, Ricardo U. Sorensen, MD, James W. Verbsky, MD, PhD, David I. Bernstein, MD, Joann Blessing-Moore, MD, David Lang, MD, Richard A. Nicklas, MD, John Oppenheimer, MD, Jay M. Portnoy, MD, Christopher R. Randolph, MD, Diane Schuller, MD, Sheldon L. Spector, MD, Stephen Tilles, MD, Dana Wallace, MD Chief Editor: Francisco A. Bonilla, MD, PhD Co-Editor: David A. Khan, MD Members of the Joint Task Force on Practice Parameters: David I. Bernstein, MD, Joann Blessing-Moore, MD, David Khan, MD, David Lang, MD, Richard A. Nicklas, MD, John Oppenheimer, MD, Jay M. Portnoy, MD, Christopher R. Randolph, MD, Diane Schuller, MD, Sheldon L. Spector, MD, Stephen Tilles, MD, Dana Wallace, MD Primary Immunodeficiency Workgroup: Chairman: Francisco A. Bonilla, MD, PhD Members: Zuhair K. Ballas, MD, Javier Chinen, MD, PhD, Michael M. Frank, MD, Joyce T. Hsu, MD, Michael Keller, MD, Lisa J. Kobrynski, MD, Hirsh D. Komarow, MD, Bruce Mazer, MD, Robert P. Nelson, Jr, MD, Jordan S. Orange, MD, PhD, John M. Routes, MD, William T. Shearer, MD, PhD, Ricardo U. Sorensen, MD, James W. Verbsky, MD, PhD GlaxoSmithKline, Merck, and Aerocrine; has received payment for lectures from Genentech/ These parameters were developed by the Joint Task Force on Practice Parameters, representing Novartis, GlaxoSmithKline, and Merck; and has received research support from Genentech/ the American Academy of Allergy, Asthma & Immunology; the American College of Novartis and Merck.
  • Most Variable Genes and Transcription Factors in Acute Lymphoblastic Leukemia Patients

    Most Variable Genes and Transcription Factors in Acute Lymphoblastic Leukemia Patients

    Interdisciplinary Sciences: Computational Life Sciences https://doi.org/10.1007/s12539-019-00325-y ORIGINAL RESEARCH ARTICLE Most Variable Genes and Transcription Factors in Acute Lymphoblastic Leukemia Patients Anil Kumar Tomar1 · Rahul Agarwal2 · Bishwajit Kundu1 Received: 24 September 2018 / Revised: 21 January 2019 / Accepted: 26 February 2019 © International Association of Scientists in the Interdisciplinary Areas 2019 Abstract Acute lymphoblastic leukemia (ALL) is a hematologic tumor caused by cell cycle aberrations due to accumulating genetic disturbances in the expression of transcription factors (TFs), signaling oncogenes and tumor suppressors. Though survival rate in childhood ALL patients is increased up to 80% with recent medical advances, treatment of adults and childhood relapse cases still remains challenging. Here, we have performed bioinformatics analysis of 207 ALL patients’ mRNA expression data retrieved from the ICGC data portal with an objective to mark out the decisive genes and pathways responsible for ALL pathogenesis and aggression. For analysis, 3361 most variable genes, including 276 transcription factors (out of 16,807 genes) were sorted based on the coefcient of variance. Silhouette width analysis classifed 207 ALL patients into 6 subtypes and heat map analysis suggests a need of large and multicenter dataset for non-overlapping subtype classifcation. Overall, 265 GO terms and 32 KEGG pathways were enriched. The lists were dominated by cancer-associated entries and highlight crucial genes and pathways that can be targeted for designing more specifc ALL therapeutics. Diferential gene expression analysis identifed upregulation of two important genes, JCHAIN and CRLF2 in dead patients’ cohort suggesting their pos- sible involvement in diferent clinical outcomes in ALL patients undergoing the same treatment.
  • WO 2015/007520 Al 22 January 2015 (22.01.2015) P O P C T

    WO 2015/007520 Al 22 January 2015 (22.01.2015) P O P C T

    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2015/007520 Al 22 January 2015 (22.01.2015) P O P C T (51) International Patent Classification: lon, F-34095 Montpellier (FR). GARCIN, Genevieve; Rue C07K 16/46 (2006.01) C07K 19/00 (2006.01) de Tyr 89, Montpellier, 34090 (FR). (21) International Application Number: (74) Common Representative: VIB VZW; Rijvisschestraat PCT/EP2014/063976 120, B-9052 Gent (BE). (22) International Filing Date: (81) Designated States (unless otherwise indicated, for every 1 July 2014 (01 .07.2014) kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, (25) Filing Language: English BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, (26) Publication Language: English DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, (30) Priority Data: KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, 13306045.9 19 July 2013 (19.07.2013) EP MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, (71) Applicants: VIB VZW [BE/BE]; Rijvisschestraat 120, B- OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, 9052 Gent (BE). UNIVERSITEIT GENT [BE/BE]; Sint- SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, Pietersnieuwstraat 25, B-9000 Gent (BE). CENTRE NA¬ TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, TIONAL DE LA RECHERCHE SCIENTIFIQUE ZW.
  • Genetic Alterations in High-Risk B-Progenitor Acute Lymphoblastic Leukemia

    Genetic Alterations in High-Risk B-Progenitor Acute Lymphoblastic Leukemia

    SECTION A Genetic Alterations in High-Risk B-Progenitor Acute Lymphoblastic Leukemia Charles G. Mullighan Abstract adulthood, cure rates for ALL fall sharply, and the genetic and biologic determinants of Recent studies profiling genetic alterations in treatment failure remain incompletely B-progenitor acute lymphoblastic leukemia understood (8,9). (B-ALL) at high resolution have identified multiple recurring submicroscopic genetic alterations ALL has long been exceptionally well targeting key cellular pathways in lymphoid cell characterized at the cytogenetic level, and growth, differentiation and tumor suppression. approximately three quarters of childhood ALL A key finding has been that genetic alterations cases harbor recurring gross genetic alterations, disrupting normal lymphoid growth and including chromosomal aneuploidy (high differentiation and are associated with treatment hyperdiploidy and hypodiploidy), and outcome. Notably, genetic alterations targeting rearrangements that dysregulate hematopoietic lymphoid development are present in over two- regulators, transcription factors, and tyrosine thirds of B-ALL cases, including deletions, kinases. These include rearrangements resulting translocations and sequence mutations of the in (e.g. ETV6-RUNX1, TCF3-PBX1, BCR-ABL1, transcriptional regulators PAX5, IKZF1, and EBF1. rearrangement of MLL, and rearrangements of Deletion or mutation of the early lymphoid T cell receptor genes to hematopoietic regulators transcription factor gene IKZF1 is hallmark of and transcription factors in T-lineage ALL) multiple subtypes of ALL with poor prognosis, (10,11). While alterations associated with including BCR-ABL1 positive (Ph+) lymphoid favorable outcome (e.g. high hyperdiploidy and leukemia and a novel subset of BCR-ABL1-like ETV6-RUNX1) are characteristic of childhood ALL cases that have a gene expression profile ALL, and the frequency of BCR-ABL1 similar to that of Ph+ B-ALL, but lack expression (Philadelphia chromosome positive, or Ph+) ALL of BCR-ABL1.
  • Innate Lymphoid Cells: Transcriptional Profiles and Cytokine Developmental Requirements Michelle Lauren Robinette Washington University in St

    Innate Lymphoid Cells: Transcriptional Profiles and Cytokine Developmental Requirements Michelle Lauren Robinette Washington University in St

    Washington University in St. Louis Washington University Open Scholarship Arts & Sciences Electronic Theses and Dissertations Arts & Sciences Spring 5-15-2018 Innate Lymphoid Cells: Transcriptional Profiles and Cytokine Developmental Requirements Michelle Lauren Robinette Washington University in St. Louis Follow this and additional works at: https://openscholarship.wustl.edu/art_sci_etds Part of the Allergy and Immunology Commons, Immunology and Infectious Disease Commons, and the Medical Immunology Commons Recommended Citation Robinette, Michelle Lauren, "Innate Lymphoid Cells: Transcriptional Profiles and Cytokine Developmental Requirements" (2018). Arts & Sciences Electronic Theses and Dissertations. 1571. https://openscholarship.wustl.edu/art_sci_etds/1571 This Dissertation is brought to you for free and open access by the Arts & Sciences at Washington University Open Scholarship. It has been accepted for inclusion in Arts & Sciences Electronic Theses and Dissertations by an authorized administrator of Washington University Open Scholarship. For more information, please contact [email protected]. WASHINGTON UNIVERSITY IN ST. LOUIS Division of Biology and Biomedical Sciences Immunology Dissertation Examination Committee: Marco Colonna, Chair Maxim Artyomov Takeshi Egawa Gwen Randolph Wayne Yokoyama Innate Lymphoid Cells: Transcriptional Profiles and Cytokine Developmental Requirements by Michelle Lauren Robinette A dissertation presented to The Graduate School of Washington University in partial fulfillment of the requirements
  • Functional Screening Identifies CRLF2 in Precursor B-Cell Acute

    Functional Screening Identifies CRLF2 in Precursor B-Cell Acute

    Functional screening identifies CRLF2 in precursor B-cell acute lymphoblastic leukemia Akinori Yodaa, Yuka Yodaa, Sabina Chiarettib, Michal Bar-Natana, Kartik Mania, Scott J. Rodigc, Nathan Westa, Yun Xiaoc, Jennifer R. Browna, Constantine Mitsiadesa, Martin Sattlera, Jeffrey L. Kutokc, Daniel J. DeAngeloa, Martha Wadleigha, Alfonso Piciocchid, Paola Dal Cinc, James E. Bradnera, James D. Griffina, Kenneth C. Andersona, Richard M. Stonea, Jerome Ritza, Robin Foàb, Jon C. Asterc, David A. Franka, and David M. Weinstocka,1 aDepartment of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115; bDivision of Hematology, Department of Cellular Biotechnologies and Hematology, “Sapienza” University of Rome, 00185 Rome, Italy; cDepartment of Pathology, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA 02115; and dGruppo Malattie Ematologiche dell’Adulto Data Center, 00161 Rome, Italy Edited by Ross Levine, Memorial Sloan-Kettering Cancer Center, and accepted by the Editorial Board November 12, 2009 (received for review October 9, 2009) The prognosis for adults with precursor B-cell acute lymphoblastic which is believed to serve as a scaffold. As a consequence, JAK leukemia (B-ALL) remains poor, in part from a lack of therapeutic gain-of-function mutants do not confer a transformed phenotype targets. We identified the type I cytokine receptor subunit CRLF2 in the absence of a compatible cytokine receptor (16). in a functional screen for B-ALL–derived mRNA transcripts that can We performed a retroviral cDNA library screen to identify substitute for IL3 signaling. We demonstrate that CRLF2 is overex- gain-of-function mutations from primary B-ALL specimens. We pressed in approximately 15% of adult and high-risk pediatric B- made several improvements to older approaches that increase ALL that lack MLL, TCF3, TEL, and BCR/ABL rearrangements, but the efficiency of library construction and cDNA representation.
  • IL2RG Hypomorphic Mutation: Identifcation of a Novel Pathogenic Mutation in Exon 8 and a Review of the Literature Che Kang Lim1,2†, Hassan Abolhassani1,3†, Sofa K

    IL2RG Hypomorphic Mutation: Identifcation of a Novel Pathogenic Mutation in Exon 8 and a Review of the Literature Che Kang Lim1,2†, Hassan Abolhassani1,3†, Sofa K

    Lim et al. Allergy Asthma Clin Immunol (2019) 15:2 Allergy, Asthma & Clinical Immunology https://doi.org/10.1186/s13223-018-0317-y CASE REPORT Open Access IL2RG hypomorphic mutation: identifcation of a novel pathogenic mutation in exon 8 and a review of the literature Che Kang Lim1,2†, Hassan Abolhassani1,3†, Sofa K. Appelberg1, Mikael Sundin4,5 and Lennart Hammarström1,6* Abstract Background: Atypical X-linked severe combined immunodefciency (X-SCID) is a variant of cellular immunodefciency due to hypomorphic mutations in the interleukin 2 receptor gamma (IL2RG) gene. Due to a leaky clinical phenotype, diagnosis and appropriate treatment are challenging in these patients. low Case presentation: We report a 16-year-old patient with a ­T ­B+ ­NK+ cellular immunodefciency due to a novel nonsense mutation in exon 8 (p.R328X) of the IL2RG gene. Functional impairment of the IL2RG was confrmed by IL2-Janus kinase 3-signal transducer and activator of transcription signaling pathway investigation. In addition, the characteristics of the mutations previously described in 39 patients with an atypical phenotype were reviewed and analyzed from the literature. Conclusion: This is the frst report of an atypical X-SCID phenotype due to an exon 8 mutation in the IL2RG gene. The variability in the phenotypic spectrum of classic X-SCID associated gene highlights the necessity of multi-disciplinary cooperation vigilance for a more accurate diagnostic workup. Keywords: Interleukin 2 receptor gamma, Atypical severe combined immunodefciency, Hypomorphic mutations Background mutations lead to the production of a nonfunctional γC Interleukin 2 receptor gamma (IL2RG) is an important or prevent the protein from being produced, resulting in signaling component for IL2, IL4, IL7, IL9, IL15, and an arrest in lymphocyte development.